PT - JOURNAL ARTICLE AU - MAYER, SEBASTIAN AU - GABRIEL, BORIS AU - ERBES, THALIA AU - TIMME-BRONSERT, SYLVIA AU - JÄGER, MARKUS AU - RÜCKER, GERTA AU - KUF, FRANCISKA AU - BOUDA, JIRI AU - BARTAKOVA, ALENA AU - HAUSEN, AXEL ZUR AU - STICKELER, ELMAR AU - GITSCH, GERALD AU - HIRSCHFELD, MARC TI - Cyr61 Expression Pattern and Association with Clinicopathological Factors in Patients with Cervical Cancer DP - 2017 May 01 TA - Anticancer Research PG - 2451--2456 VI - 37 IP - 5 4099 - http://ar.iiarjournals.org/content/37/5/2451.short 4100 - http://ar.iiarjournals.org/content/37/5/2451.full SO - Anticancer Res2017 May 01; 37 AB - Background/Aim: The pro-angiogenic Cyr61 protein has been associated with tumorigenesis and cancer progression in different gynecological carcinomas. In this study, we evaluated the potential impact and clinical relevance of Cyr61 expression in patients with primary non-metastatic cervical cancer (CC). Patients and Methods: Cyr61 expression was assessed in tissue specimen of 48 patients with primary CC by immunohistochemical analysis. Expression levels were scored and correlated to clinico-pathological factors and outcome data. Results: High Cyr61 expression levels were present in 54.2% of CC tissues. Associations with histological grade (p=0.030), depth of tumor invasion (p=0.007) and GOG score (p=0.027) were observed. Patients who overexpressed Cyr61 displayed an increased death rate (30.8% vs. 18.2%) and a decreased 5-year-survival (76.9% vs. 86.4%). Conclusion: Our data indicate a potential functional impact of Cyr61 in development and the progression of CC. The definite tumor-relevant function (suppressive/promoting) of Cyr61 in CC and the prognostic relevance of Cyr61 overexpression has to be evaluated in larger cohorts.